Patient with decompensated hepatitis C virus–related cirrhosis delisted for liver transplantation after successful sofosbuvir‐based treatment

Ruiz, Isaac; Féray, Cyrille; Pawlotsky, Jean‐Michel; Hézode, Christophe

doi:10.1002/lt.24051

Cited by 32 publications

(31 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, currently available data of delisting from the LT list are scarce. 71 Pretransplant treatment of HCV infection: While treatment of HCV in patients listed for transplant had been shown to prevent or decrease HCV recurrence after transplant, even in the pre-DAA era, the advent of DAAs has greatly simplified treatment of HCV of patients listed for liver transplant. Curry et al 72 demonstrated that SOF and RBV given before LT resulted in good post-transplant virological response (PTVR) and prevented HCV recurrence.…”

Section: Decompensated Cirrhosismentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

Section: Decompensated Cirrhosismentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…Data on delisting from the LT list are scarce but accumulating. 62 Initial report was from France that described a patient with MELD score 16, refractory ascites, encephalopathy who was listed for transplantation in October 2013. Patient was treated with SOF + RBV in December 2013 and was given for 24 weeks.…”

Section: Improvement In Portal Hypertensionmentioning

confidence: 99%

Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Anand

2017

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…The recurrence was related inversely to the number of consecutive days of undetectable HCV RNA before transplantation [61] . There has also been reported case of decompensated patient improving to the point of being delisted after treatment with sofosbuvir and ribavirin for 24 wk [62] .…”

Section: Patients On the Liver Transplant Waiting Listmentioning

confidence: 99%

Era of direct acting antivirals in chronic hepatitis C: Who will benefit?

Fung

2015

WJH

View full text Add to dashboard Cite

In the era of highly effective direct acting antiviral (DAA) drugs for the treatment of chronic hepatitis C (CHC) infection, where eradication is almost ensured with minimal side effects, all hepatitis C carriers should benefit theoretically. In the real world setting however, only a small proportion will benefit at this time point due to the multiple barriers to accessing therapy. Given that universal treatment is unlikely, treatment with DAAs will likely be restricted to those with the highest health benefits, and for those who can afford the high expense of a treatment course. Those with the highest unmet needs include those who have failed previous interferon-based therapy or who are interferon-ineligible with evidence of active disease, those with advance liver disease, and those with recurrence of hepatitis C after liver transplantation. In the future, the focus should be on increasing access to treatment for those infected with CHC.

show abstract

Patient with decompensated hepatitis C virus–related cirrhosis delisted for liver transplantation after successful sofosbuvir‐based treatment

Cited by 32 publications

References 5 publications

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Era of direct acting antivirals in chronic hepatitis C: Who will benefit?

Contact Info

Product

Resources

About